Rosanna Paciucci Barzanti Institucions de les que formen part Investigador/a principal Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia Vall Hebron Institut de Recerca Email Rosanna Paciucci Barzanti Email Institucions de les que formen part Investigador/a principal Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia Vall Hebron Institut de Recerca
Línies de recerca Recerca i implantació clínica de nous biomarcadors IP: Rosanna Paciucci Barzanti, Yolanda Villena Ortiz Cell signaling and cancer progression Prostate cancer (PC) is the second leading cause of death for cancer in men of the western Countries. While considerable advances have been made in the treatment of localized, organ-confined tumors, metastatic PC is virtually incurable and most deaths from this disease are due to the high resistance of metastasis to conventional therapies (androgen-depletion-therapy, ADT). Therefore, more precise markers for the detection of the incipient resistant tumor and more effective targets that eliminate the resistant clones are needed. A principal aim is to identify relevant molecular pathways specifically active in aggressive prostate cancer, useful for an early detection of ADT resistant tumors and for treatment strategies. In our studies, we have discovered the human Prostate Tumor OVerexpressed-1 (PTOV1) gene, later called Acid-2, and a second gene with a PTOV module, PTOV2, later called MED25, a component of Mediator (1-2). The detection of PTOV1 in high-grade PIN (HGPIN) premalignant lesions is helpful to identify patients with higher probability to develop PC (3). PTOV1 ectopic expression promotes proliferation, invasion and metastasis of ADT resistant cells (1,2,4,5). PTOV1 induces the epithelial-mesenchymal-transition (EMT) and increased metastasis of PC3 cells (4). Mechanistically, PTOV1 is implicated in multiple processes controlling cell fate: it promotes mRNA translation leading to a specific increased synthesis of c-Jun and Snai1 oncogenes (4), and it is a transcriptional repressor of HES1 and HEY1 genes, leading to inhibition of Notch signalling in metastatic PC (5). PTOV1 significantly affect the self-renewal potential of the cancer stem cell populations of PC3 cells (5). Current objectives of our line of research are: (i) Determine the role of PTOV1 in the resistance to ADT and chemotherapy (taxols). (ii) Characterize the sub-clonal cancer stem cell populations (CSC) present in metastatic primary tumors and the genes and factors responsible for the development of the resistance to ADT. 1) Benedit P, et al. Oncogene 2001;20:1455–1464. 2) Santamaria A, et al. Am J Pathol 2003;162:897–905. 3) Morote J, et al. Clin Cancer Res 2008:14:2617-2622. 4) Marqués N, et al. Oncogene 2014;33(9):1124-34. 5) Alaña L et al., Mol Cancer 2014;13:74. IP: Rosanna Paciucci Barzanti Projectes Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT) IP: Ibane Abasolo Olaortua Col·laboradors: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora Entitat finançadora: Agència Gestió Ajuts Universitaris i de Recerca Finançament: 60000 Referència: 2021 SGR 01173 Durada: 01/01/2022 - 30/06/2025 Detección temprana de recurrencia para una terapia personalizada en pacientes hormono-sensibles con cáncer de próstata metastásico. IP: Rosanna Paciucci Barzanti Col·laboradors: Luisa Maria Martinez Sánchez, Maria Eugenia Semidey Raven, Jacques Planas Morin Entitat finançadora: Ministerio Economía, Industria y Competitividad Finançament: 108900 Referència: RTI2018-096055-B-I00 Durada: 01/01/2019 - 30/09/2022 Biomarquers and targets of resistant prostate cancer IP: Rosanna Paciucci Barzanti Col·laboradors: - Entitat finançadora: Agència Gestió Ajuts Universitaris i de Recerca Finançament: 0.01 Referència: 2017SGR01411 Durada: 01/01/2017 - 31/12/2020 El estrés terapeútico como generador de resistencia en las células madre neoplásicas prostáticas: marcadores predictivos de resistencia y dianas terapéuticas IP: Rosanna Paciucci Barzanti Col·laboradors: Inés de Torres Ramirez, Jacques Planas Morin Entitat finançadora: Ministerio Economía, Industria y Competitividad Finançament: 181500 Referència: SAF2014-59958-R Durada: 01/01/2015 - 31/12/2017 Paginació Pàgina actual 1 Page 2 Page 3 Page 4 Page 5 … Pàgina següent › Última pàgina »
